Prominent corneal nerves are a diagnostic feature of LP

Article

Prominent corneal nerves have been identified as a diagnostic feature of lipid proteinosis (LP)

Prominent corneal nerves have been identified as a diagnostic feature of lipid proteinosis (LP), claims a study in the British Journal of Ophthalmology.

Dr Yasser H. Al-Faky et al., Ophthalmology Department, College of Medicine, King Saud University, Saudi Arabia, conducted a detailed longitudinal evaluation of seven LP patients and nine unaffected individuals. The Nidek confoScan 4 and direct sequencing of the extracellular matrix protein 1 gene was used to perform confocal microscopic examinations.

All LP patients had homozygous mutations in extracellular matrix protein 1 and four patients were examined every six months, starting from infancy. It was discovered that globe and vision were normal in all particpants, with moniliform blepharosis appearing after four years of age.

All patients presented with prominent corneal nerves, regardless of age. The corneal nerves were more prominent in patients with severe genetic mutations. Severity of moniliform blepharosis appeared to be more affected by age rather than genotype.

The discovery of prominent corneal nerves as a diagnostic feature can be used to detect LP at a much earlier stage.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.